SEATTLE, May 27 /PRNewswire/ -- The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research institute, is very pleased to announce that Steve Davis has joined its team as Interim CEO, to assist the organization in its strategic development as a non-profit, product-oriented biotech innovator in global health.
"Steve will be an incredible asset to IDRI," indicated Steve Reed, IDRI's Founder and Head of Research & Development. "He can help take IDRI to the next level and greatly expand our presence in Seattle and the world as we continue to develop great diagnostics and products to save lives around the world."
Steve Davis comes to IDRI in the institute's fifteenth year and brings with him an impressive and diverse career track. Davis has studied Chinese language and law, has served as an advocate in the fields of international refugee and human rights, and has long-held experience in the field of intellectual property.
Most recently, as former CEO of Corbis Corporation, Davis led the small startup company founded in 1989 by Bill Gates to become a leader in the industry of photography, art, and footage rights; today Corbis has approximately 1,000 employees and serves over 50 countries worldwide. Additionally, Davis sits on numerous corporate boards, both profit and non-profit, including the Program for Appropriate Technology in Health (PATH), the Fred Hutchinson Cancer Research Center, The Seattle Foundation, Global Partnerships, Intrepid Learning Solutions, Crucell, Inc., and PlanetOut, Inc. In addition, he currently consults on strategic management issues for several organizations and is a lecturer at the University of Washington's School of Law. He holds degrees from Princeton, University of Washington, and Columbia Law School, and attended certificate programs at Stanford University and Beijing University.
IDRI's board of directors is convinced that Davis' leadership skills and innovative thinking will advance the institute's goals.
Davis plans to help IDRI increase its presence in the biotech and public health communities, as well as enhance IDRI's strategy and organization. "IDRI is an increasingly important player in the global health and research community," Davis says. "Its non-profit biotech model is different from other more well-known scientific research organizations that focus on bench science.
IDRI's goal to create vaccines, therapeutics, and diagnostics for diseases that affect the world's poorest people is powerful. The team here has previously delivered in a number of areas in infectious diseases in the past, and many scientists here have experience in industry. IDRI is clearly an asset for the world of neglected diseases."
IDRI is a non-profit organization committed to developing technologies to treat "neglected" diseases that place a significant burden on those living in the developing world. IDRI achieves its mission by working closely with industry, universities, and hospitals in developed and developing countries, government and private funding agencies, and the World Health Organization. For more information, go to http://www.idri.org.
|SOURCE Infectious Disease Research Institute|
Copyright©2008 PR Newswire.
All rights reserved